Sanofi - ADR (SNY): Price and Financial Metrics
Sanofi - ADR (SNY)
Today's Latest Price: $50.14 USD
Updated Oct 19 9:50pm
Add SNY to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SNY Stock Summary
- Sanofi's market capitalization of $126,059,729,380 is ahead of 98.49% of US-listed equities.
- With a year-over-year growth in debt of 54.84%, Sanofi's debt growth rate surpasses 81.14% of about US stocks.
- In terms of volatility of its share price, SNY is more volatile than just 1.17% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Sanofi, a group of peers worth examining would be BMY, AZN, AMGN, IBM, and MDT.
- Visit SNY's SEC page to see the company's official filings. To visit the company's web site, go to www.sanofi.com.
SNY Stock Price Chart Interactive Chart >
SNY Price/Volume Stats
| Current price | $50.14 | 52-week high | $55.00 |
| Prev. close | $50.27 | 52-week low | $37.62 |
| Day low | $50.04 | Volume | 787,900 |
| Day high | $51.01 | Avg. volume | 1,737,842 |
| 50-day MA | $50.88 | Dividend yield | 2.33% |
| 200-day MA | $49.39 | Market Cap | 125.56B |
Sanofi - ADR (SNY) Company Bio
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.
SNY Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $50.14 | $61.43 | 22% |
We started the process of determining a valid price forecast for Sanofi with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Sanofi ranked in the 51th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 22.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for Sanofi ended up being:
- In the past 4.99 years, Sanofi has a compound free cash flow growth rate of 0.02%; that's higher than merely 21.74% of free cash flow generating stocks in the Healthcare sector.
- Sanofi's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 8.41% of tickers in our DCF set.
- SNY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than only 8.41% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 20% |
| 1% | 21% |
| 2% | 22% |
| 3% | 23% |
| 4% | 25% |
| 5% | 26% |
DYNT, HRC, LH, CBPO, and ENSG can be thought of as valuation peers to SNY, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...